20/20 Biolabs, Inc. (AIDX) Stock Forecast
AIDX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $5.00 average of analyst targets
- Upside to target
- +1,823.1% from the latest close
- Next earnings
- November 13, 2026
- 52-week range
- $0.26 – $23.85
AIDX analyst ratings
1 analystsNumber of analysts at each rating.
AIDX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AIDX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.06 | −$0.06 | — | — | 1 |
| Current fiscal year (2026) | −$0.42 | −$0.42 | −$0.42 | −$0.76 | +44.7% | 1 |
| Next fiscal year (2027) | −$0.38 | −$0.38 | −$0.38 | −$0.42 | +9.5% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AIDX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $891,000 | $891,000 | $891,000 | — | 1 |
| Current fiscal year (2026) | $2.9M | $2.9M | $2.9M | — | 1 |
| Next fiscal year (2027) | $5.8M | $5.8M | $5.8M | +95.7% | 1 |
AIDX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AIDX revenue: reported and forecast
AIDX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | −$0.06 | −$0.06 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | $0.00 | −$0.30 | −$0.42 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | −$0.33 | −$0.38 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AIDX earnings surprises
Reported EPS vs the consensus estimate for the last 3 quarters; AIDX beat in 0 of 2.
What analysts expect from AIDX
1 analysts cover 20/20 Biolabs; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.00, 1,823.1% above the latest close of $0.26. Analysts expect earnings of −$0.42 per share for 2026, +44.7% from a year earlier. For 2027 the average estimate is −$0.38 per share on revenue of $5.8 million. 20/20 Biolabs beat the EPS estimate in 0 of the last 2 quarters.
Related: AIDX income statement, AIDX key metrics, AIDX chart. See the AIDX stock overview for the latest quote and news.
AIDX forecast FAQ
What is 20/20 Biolabs's price target?
The average analyst price target for 20/20 Biolabs is $5.00, 1,823.1% above the latest close of $0.26.
Is 20/20 Biolabs a buy, hold or sell?
Of 1 analysts covering 20/20 Biolabs, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is 20/20 Biolabs's EPS forecast?
Analysts forecast −$0.42 per share for 2026 (range −$0.42 to −$0.42); for 2027 the estimate is −$0.38.
What is 20/20 Biolabs's revenue forecast?
The average revenue estimate for 2026 is $2.9 million; for 2027 it is $5.8 million.
When does 20/20 Biolabs report earnings?
20/20 Biolabs is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
Does 20/20 Biolabs usually beat earnings estimates?
20/20 Biolabs reported EPS at or above the analyst estimate in 0 of the last 2 quarters.